Carvedilol is non-selective alpha and beta-adrenergic antagonist with antioxydative properties. We observed 100 patients with dilatative ischaemic cardiomyopathia, rhythm disturbances and heart failure in last 5 years. Patients were analyzed before and after treatment with Carvedilol by gender, age, NYHA class and rhythm disturbances, radiological, echocardiography, clinical parameters and mortality. We found that Carvedilol improved NYHA class in majority of patients and also improved hemodinamic, EF LV. Important role of Carvedilol is conversion of heart rhythm when it was combined with diuretics, cardiotonics and antiarrhythmics (especially in atrial fibrillation and undulation) which are frequent in those patients. We didn't notice significant side effects of this medication in our patients. Carvedilol significantly improve systolic dysfunction in all observed groups of patients in different grade and significantly improve myocardial tonisation with x-ray signs of smaller heart contour.
Keywords: carvedilol, systolic function, atrial fibrillation, dilatative cardiomyopathia.